Bone Biologics Corp. (BBLG): Market Cap to Revenue
Bone Biologics is betting on internal R&D without utilizing M&A. The business valuation based on P/S, derived on GURU.Markets, demonstrates the asset's dynamics, where serves as the base parameter value. Unique proteins for tissue regeneration ensure the firm's stability, while the implementation of AI platforms and robotics in laboratories automates quality control for orthopedic materials.
Analytical breakdowns for Bone Biologics Corporation (BBLG)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Bone Biologics|BBLG - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Bone Biologics Inc|BBLG - Company Aggregate Debts|Debts to Book Capitalization Bone Biologics Corporation|BBLG - Company Long-Term Debt|Company Short-Term Debt Bone Biologics|Intermediate Coverage Ratio bonebiologics.com
- earnings and multiples data:
BBLG - Net Profit|Expected Net Profit Bone Biologics|BBLG - Price to Earnings Ratio|Forward Price to Earnings Multiple Bone Biologics Corp.|BBLG - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Bone Biologics Corporation|BBLG - Operating profit EBITDA|Net earnings per share for the last four quarters Bone Biologics|BBLG - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months bonebiologics.com|BBLG - Earnings per share growth in current year|Expected earnings per share growth for next year Bone Biologics
- issuer revenue and sales details:
General company analysis:BBLG bonebiologics.com
Stable demand for Bone Biologics (BBLG) biopolymer matrices, anchored in surgical standards, creates a predictable cash flow that the P/S ratio compares with current capitalization to identify market overheating. By analyzing the price-to-sales ratio dynamics on GURU.Markets, an investor determines the degree of business overvaluation to avoid buying the asset at its peak and to minimize the risk of capital freeze during a correction.
Competitors of Bone Biologics
BSX (bostonscientific.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Edwards Lifesciences Corporation EW|RMD - Market Cap to Revenue|OmniPod - P/S Multiple|Price to Sales Zimmer Biomet Holdings|COO: P/S Multiple|Market Cap to Revenue Ratio ALGN|GMED (Globus Medical) - P/S Multiple|TransMedics Group Inc (TMDX) - Price-to-Revenue Coefficient|P/S Multiple ATEC|Market Cap to Revenue Artivion Corp AORT|P/S Multiple ENOV (Enovis Corporation)|P/S Multiple integralife.com IART|ESTA - Price-to-Revenue Ratio|BBNX: Price-to-Revenue Ratio|IRMD (Iradimed) - Market Cap to Revenue|Embecta Health - Market Capitalization-to-Revenue Ratio|TNDM (Tandem Diabetes Care) - P/S Multiple|Price to Sales axogeninc.com AXGN|Price-to-Revenue Ratio SI-BONE (SIBN)|Orthofix Medical (OFIX) - Price-to-Revenue Multiple|Bioventus Corp - Market Cap to Revenue|P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - P/S Multiple|Price-to-Revenue Coefficient blade.com SRTA|Carlsmed (CARL) - Price-to-Revenue Ratio|Price-to-Sales Ratio RXST (RxSight Inc)|Price-to-Revenue Ratio ClearPoint Neuro Inc.|Market Cap to Revenue Stereotaxis Corporation (STXS)|P/S Multiple STIM|SGHT - Price to Sales|Price-to-Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Revenue Ratio|NSPR: Market Cap to Revenue|Jin Medical International - Market Cap to Sales Volume|VANI: P/S Multiple|XTNT (Xtant Medical) - Price-to-Revenue Ratio|Price-to-Revenue Ratio NeuroOne Medical Technologies Corporation|Price to Sales Modular Med MODD|Price-to-Revenue Ratio Myomo, Inc (MYO)|Envoy Medical Inc - Market Cap to Revenue Ratio|P/S Multiple VVOS (Vivos Therapeutics)|envveno.com (NVNO) - Price to Sales|SINT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TNON (Tenon Medical Inc.)|LFWD: P/S Multiple|AMIX (Autonomix Medical) - Price-to-Revenue Ratio|IVF (INVO Fertility Inc) - P/S Multiple|axonics.com (AXNX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio BIOLASE (BIOL)|DYNT - Price to Sales|Price-to-Revenue Ratio Paragon 28 FNA|INVO Bioscience Inc. - Price-to-Revenue Ratio
